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Background: Women with polycystic ovary syndrome (PCOS) are generally insulin- resistant and are consequently
often treated with metformin. We investigated the effect of metformin and AICAR on the AMP-activated protein
kinase (AMPK) pathway.
Methods: We evaluated the effects of 5-amino-imidazole-4-carboxyamide-1- beta-D-ribofuranoside (AICAR) and
metformin on tumor necrosis factor (TNF)-alpha- stimulated chemokine production in human granulosa cells. The
phosphorylations of AMPK, I-kappaB, 4E-BP-1, p70S6K were analyzed by western immunoblotting.
Results: AICAR and metformin markedly reduced the IL-8 and GROalpha production induced by TNF-alpha. AICAR
and metformin also reduced the TNF-alpha-induced phosphorylation of I-kappaB. The phosphorylations of I-kappaB,
4EBP-1, p70S6K were inhibited via an AMPK-dependent signal transduction.
Conclusions: These results suggest that metformin promotes granulosa cell function by reducing a TNF-alpha- and
chemokine-mediated inflammatory reaction through an AMPK-dependent pathway. These finding may have implications
for metformin’s actions during the treatment of PCOS with metformin.
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The ovarian cycle is characterized by repeating patterns
of cellular proliferation and differentiation that accom-
pany follicular development as well as ovulation under
the appropriate gonadotropin stimulation. Follicular de-
velopment begins when the granulosa cells start to
proliferate.
It was demonstrated that inflammatory reaction based
on gene regulation is observed in polycystic ovary syn-
drome (PCOS) [1]. It was also reported that gene variants
in several proinflammatory cytokines and their receptors,
which have been recognized to be related with insulin re-
sistance, obesity, and diabetes were found in PCOS [2]. In
addition, results in gene variants of tumor necrosis factor
(TNF)-α [2], type 2 TNF receptor [3], and IL-6 [4] pro-
vided supportive evidence that these factors were associ-
ated with PCOS in European populations.* Correspondence: kawayas@oita-u.ac.jp
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unless otherwise stated.It has been demonstrated that not all PCOS women
are generally insulin-resistant, and PCOS is often treated
with the oral biguanide metformin [5]. The systemic
antihyperglycemic and insulin-sensitizing effects of met-
formin are well recognized [6]. However, the results of
metformin treatment for women with PCOS have been
variable, with some studies demonstrating induction of
regular menstrual cycles and increases in both ovulation
and live birth rates [7,8], versus other studies that
showed no significant effect on ovulation [9-11].
Metformin is an antihyperglycemic medication that
was first approved for use in 1995 and has since become
a mainstay in the treatment of type 2 diabetes [11]. Met-
formin has also proven to be useful in the treatment of
PCOS. It was shown to induce the regularity of men-
strual cycles, improve hyperinsulinemia, and attenuate
hyperandrogenemia in clinical studies of women with
PCOS [12,13]. The exact mechanism by which metfor-
min improves ovarian function remains unclear.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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known as a pharmacological activator of a adenosine mono-
phosphate (AMP)-activated protein kinase (AMPK) [14].
AMPK is an energy-sensing enzyme with heterotrimeric
complex that is believed to be directly implicated in the
regulation of energy metabolism at the intracellular and
whole-organ levels [15-17]. It has been reported that both
the energy producing pathways and the down regulation of
energy-consuming metabolic processes are activated by
AMPK [15,16]. However, the possible role of AMPK is not
clarified in granulosa cells.
Chemokines are recognized as a large superfamily of
structurally and functionally related molecules with chemo-
tactic activity targeted at specific leukocyte populations.
They are 70–90 amino acids in length and are divided into
four subfamilies based on the relative position of their cyst-
eine residues (CC, CXC, C, CXC3). The CXC chemokine
subfamily includes interleukin (IL)-8 and growth-regulated
oncogene (GRO) α, GROβ, GROγ, all of which have been
shown to chemoattract and activate neutrophils [18]. IL-8,
a potent neutrophil chemoattract and activating factor, has
been suggested to be one of the most likely agents respon-
sible for the recruitment and activation of neutrophils in
and around pre-ovulatory follicles just before ovulation
[19]. Another candidate, reported to have ten times the
potency of IL-8, as a neutrophil chemoattractant, is the
pro-inflammatory CXC chemokine GROα [20]. It has been
suggested that leukocytes may play an important role in
ovulation, luteinization, and luteolysis, as they have the cap-
acity to secrete cytokines, eicosanoids, vasoactive amines,
and tissue remodeling enzymes. Leukocyte attractant activ-
ity has been detected in ovulation; however, it has not yet
been fully characterized in human follicular fluids (FFs)
[21]. It has been reported that IL-8 and GROα were in-
creased by TNF-α [21]. The excess inflammatory change is
thought to impair the intrafollicular circumstances.
In the present study, to examine the direct effect of
metformin and AICAR on granulosa cell function, we
cultured a human granulosa-like tumor cell line and in-
vestigated the regulation of TNF-α-induced chemokine
production involving AMPK activation.
Methods
Reagents
Ham F-12 cell culture medium was purchased from
Gibco-BRL (Gaithersburg, MD, USA), and Dulbecco’s
minimal essential medium (DMEM) was purchased from
Nissui Pharmaceutical Co. (Tokyo). Fetal calf serum (FCS)
was obtained from HyClone (Logan, UT). TNF-α was ob-
tained from R&D Systems (Minneapolis, MN). The AMP
analog 5-amino-imidazole-4-carboxyamide-1-β-D-ribofur-
anoside (AICAR) was purchased from Sigma Chemicals
(St. Louis, MO) and the metformin was from Wako
(Tokyo).Cell culture
We used an immortalized granulosa cell line (KGN) that
was established at the Kyushu University School of Medi-
cine as described [22]. KGN cells were cultured in an
equal volume of Ham F-12 and DMEM (1:1, v/v) supple-
mented with 10% heat-inactivated FCS with penicillin
(100 IU/mL; Gibco-BRL) and streptomycin (100 mg/mL;
Gibco-BRL). Cells were plated in culture dishes (12-well
plates) and allowed to replicate to confluence.
The cells were then placed in the same serum-free
medium for 24 h before the stimulation with TNF-α,
AICAR, and metformin was initiated. After the desired
length of stimulation with various concentrations of TNF-α
(0.01 to 10 nM), AICAR (0.1 to 3 mM) and metformin
(0.001 to 1 mM), the culture media were collected and
stored at −80°C for the quantification of chemokines.
Measurement of IL-8 and GROα
To investigate the production of IL-8 and GROα by KGN,
we plated 5 × 105 viable KGN cells on six-well culture
plates (Corning) in 1 mL of culture medium with 10%
FCS and cultured them until they were fully confluent.
The cells were washed twice with phosphate-buffered sa-
line (PBS) without calcium and magnesium, and then
added to serum-free medium. The supernatant was re-
placed with fresh culture medium containing various con-
centrations of TNF-α, AICAR and metformin for 24 h.
Control cells received an equivalent volume of medium
alone during the incubations.
AICAR has been used as a pharmacological activator
of AMPK. It can enter cells. AICAR is thought to be
converted into 5-aminoimidazole-4-carboxamide ribo-
tide (ZMP) by adenosine kinase. ZMP can activate the
AMPK signaling pathway according to its structural
similarity with AMP [23,24].
At the end of the culture period, the medium was stored
at −80°C until assayed. These experiments were performed
in triplicate and repeated four times. A commercially avail-
able enzyme-linked immunosorbent assay (ELISA; R&D
Systems) was used to determine the amounts of IL-8 and
GROα (R&D Systems) in the supernatants. The sensitivities
of the assays for IL-8 and GROα were 0.7 pg/mL and
4.4 pg/mL, respectively. The inter- and intra-assay coeffi-
cients of variance for the ELISA of IL-8 and GROα were
10.8 and 8.2%, respectively. These experiments were per-
formed in triplicate and repeated three times.
Protein preparation of KGN and Western immunoblotting
analysis (ECL-WB)
To investigate the intracellular signal transduction system
in KGN cells, we performed a Western immunoblotting
analysis as described [25]. Briefly, 1 × 106 cells were plated
on a 100 mm dish (Nalgene Nunc, Rochester, NY) in
10 mL of culture medium with 10% FCS and cultured
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placed with fresh culture medium containing TNF-α,
AICAR and metformin. Cells were stimulated by various
concentrations of TNF-α (1 nM), AICAR (1 mM) and
metformin (0.01 to 1 mM) for 5 min to 24 h. At the end
of the culture period, the cells were washed twice with
cold PBS without calcium or magnesium, harvested,
pelleted, and lysed in ice-cold buffer containing 10 mM
HEPES (pH 7.9), 10 mM KCl, 0.1 mM ethylenediamine-
tetraacetic acid (EDTA; pH 8.0), 0.1 mM ethylene glycol
tetraacetic acid (EGTA), 1 mM dithiothreitol (DTT),
0.5 mM phenylmethanesulfonyl fluoride (PMSF), and
0.3 μg/mL leupeptin. The cell lysate was centrifuged for
10 min at 3,000 × g in order to pellet the nuclei. The
supernatant fractions were collected and centrifuged for
10 min at 10,000 × g. The protein content was deter-
mined using a microbicinchoninic acid assay (Pierce,
Rockford, IL) using bovine serum albumin (BSA) as a
standard.
The lysate was mixed with loading buffer [200 mM
Tris–HCl (pH 7.9), 7% sodium dodecyl sulfate (SDS; w/
v), 30% glycerol (v/v), 15% 2-mercaptoethanol (v/v), and
0.75% bromophenol blue (w/v)] and heated at 95°C for
10 min. In each sample, 10 μg of protein was applied
per lane. The blotted membranes were blocked in PBS
containing 5% skim milk (Difco, Detroit, MI) for 1 h at
room temperature and washed with three changes of
Tris-buffered saline (TBS; 20 mM Tris, 137 mM NaCl,
pH 7.6) buffer containing 0.1% Tween 20 for 15 min at
RT. The blotted membranes were then incubated and
reacted overnight with 1:1,000-diluted primary antibody
[human phospho-AMPK antibody, human phospho-
4EBP-1, human phospho-p70S6 kinase, rabbit poly-
clonal immunoglobulin G, human phospho-IκB-α,
mouse monoclonal immunoglobulin G (IgG; Cell Sig-
naling Technology), and human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibody, mouse
monoclonal immunoglobulin G (IgG, Ambion Austin,
TX)] in TBS containing 5% BSA at 4°C. After being
washed with three changes of TBS containing 0.1%
Tween 20, the blotted membranes were incubated and
reacted with 1:2,000-diluted peroxidase-conjugated sec-
ondary antibody (anti-rabbit or anti-mouse immuno-
globulin γ or μ chain, goat polyclonal immunoglobulin
G; Jackson Immunoresearch Laboratories, West Grove,
PA) in TBS containing 5% BSA for 1 h at RT. After the
membranes were washed with four changes of TBS con-
taining 0.1% Tween 20, Lumi GLO from a Phototope-HRP
Western Detection Kit (GE Healthcare UK, Buckingham-
shire, England) was added to the blotted membranes and
reacted for 1 min. The membranes were then covered with
plastic wrap and exposed to X-ray film (GE Healthcare UK)
for 1 to 2 min. These experiments were performed in tripli-
cate and repeated three times.Statistical analysis
Data are presented as means ± SD and were analyzed
using the Bonferroni/Dunn’s test employing StatView 4.5
software (Abacus Concepts, Berkeley, CA). P-values <0.05
were considered significant. The confidence intervals with
P-values for multiple statistical analyses are at the 95%
level.
Results
The production of IL-8 and GROα following stimulation
by TNF-α in KGN cells
We examined the effect of the addition of TNF-α at differ-
ent concentrations (0.01 to 10 nM), for 24 h on the release
of IL-8 by KGN. As illustrated in Figure 1, TNF-α at 0.1
nM and more caused an increase in IL-8 and GROα
release.
Cell counts and 5-bromo-2′- deoxyuridine uptake at
24 h were substantially the same whether or not the cells
were treated with TNF-α (data not shown). During this
period, the concentrations of IL-8 and GROα in the media
were significantly less in the control cells compared to the
TNF-α-treated cells.
AICAR and metformin decreased the IL-8 and GROα
production stimulated by TNF-α in KGN
We chose the KGN cell line to investigate whether AICAR
could prevent inflammatory mediator production, given its
role in the regulation of granulosa cells. It has been widely
reported that increased IL-8 and GROα productions are as-
sociated with inflammatory reactions. KGN cultures estab-
lished from human granulosa cell tumor were treated with
various concentrations of AICAR or metformin prior to the
addition of TNF-α. The results showed that AICAR and
metformin suppressed IL-8 and GROα production in TNF-
α-stimulated KGN cells in a concentration-dependent man-
ner (Figure 2).
AMPK phosphorylation following stimulation by AICAR and
metformin
To elucidate the role of AMPK in the KGN, we examined
the effects of AICAR and metformin on the phosphoryl-
ation of AMPK. We found that 1 mM AICAR and 1 mM
metformin activated AMPK time-dependently compared
to the controls (5 min stimulation) (Figure 3).
AICAR and metformin inhibited IκB phosphorylation
following stimulation by TNF-α in KGN cells
To elucidate the mechanism of the TNF-α-induced se-
cretions of IL-8 and GROα by KGN cells, we examined
the effects of a TNF-α-specific mechanism, the phos-
phorylation of IκB. The results of the western blot ana-
lysis demonstrated that IκB phosphorylation in KGN
was stimulated by TNF-α (1 nM) (Figure 4).
Figure 1 Dose-dependent productions of IL-8 and GROα stimulated with TNF-α. Dose-dependent productions of IL-8 (A) and GROα (B) in KGN cells
stimulated with TNF-α. Cultured cells were incubated with the indicated concentrations of TNF-α for 24 h at 37°C in 5% CO2. At the end of the incubation
period, the conditioned medium was collected and assayed for IL-8 and GROα concentrations by ELISA. The values represent the relative ratios of IL-8 and
GROα concentrations, compared with those in untreated cells after normalization with total protein. Values are the mean± SD of the combined data of four
separate experiments using different KGN preparations. A: *P < 0.01, **P < 0.001 (all vs.control). B: *P < 0.01; ** P < 0.001 (all vs. control).
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apparent when cells were pretreated with metformin for
only 0.5 h and then stimulated for 15 min with TNF-α.
As shown in Figure 4, treatment with the combination
of TNF-α and metformin resulted in reductions in the
cellular protein levels of IκB phosphorylation compared
to treatment with TNF-α alone. The expected 37 kDa
band corresponding to GAPDH is shown as the internal
control.Figure 2 Effects of AICAR and metformin on the TNF-α-induced produc
TNF-α-induced production of IL-8 and GROα in KGN. Cultured KGN were incu
of the incubation period, the conditioned medium was collected and assayed
relative ratios of IL-8 and GROα concentrations, compared with those in contr
experiments using different KGN preparations. A, B: *P < 0.001 between TNF-α
between TNF-α vs. TNF-α +Metformin (0.1 mM) or TNF-α +metformin (1 mMAICAR and metformin activated AMPK and inhibited
translocation-related proteins in KGN cells
We next examined the effects of AICAR and metformin
on mTORC1 signaling, which is negatively regulated by
AMPK and a major regulator of translation initiation.
We assessed the phosphorylation status of its two direct
downstream targets as the mTORC1 readout, p70 S6
kinase (T389) and the eukaryotic translation initiation
factor 4E (eIF4E)-binding protein 1 (4E-BP1) (T37/46).tion of IL-8 and GROα. Effects of AICAR (A) and metformin (B) on the
bated with TNF-α and/or AICAR for 24 h at 37°C in 5% CO2. At the end
for IL-8 and GROα concentrations by ELISA. The values represent the
ol cells. Values are the mean ± SD of the combined data of four separate
vs. TNF-α + AICAR (1 mM) or TNF-α + AICAR (3 mM). C, D: *P < 0.001
).
Figure 3 The phosphorylation of pAMPK. The phosphorylation of pAMPK in KGN cells treated with AICAR (1 mM) or metformin (1 mM)
for 5 min to 24 h (n = 4). GAPDH is shown as the internal control. A: Representative blots illustrating the effect of treatment on pAMPK and
GAPDH by AICAR for 5 min to 24 h. C: Representative blots illustrating the effect of treatment on pAMPK and GAPDH by metformin for 5 min to
24 h. The blot layout is in the same order as the graph in panels B and D, respectively.
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of p70S6K (T389), however metformin does not show
significant decrease the phosphorylation of p70S6K
(T389) compared to AICAR. AICAR and metformin
treatment also decreased the 4E-BP1 phosphorylation,
which was detected by anti phospho-4E-BP1 (T37/46)
antibody (Figure 5).
Discussion
Several cytokines, growth factors, and related proteins have
been identified in human follicular fluid and in the ovary
[26-28]. These molecules may exert local effects upon ste-
roidogenesis, granulosa cell proliferation, follicular growth,Figure 4 The phosphorylation of pIκB. The phosphorylation of pIκB in K
A: The phosphorylation of pIκB was quantified against GAPDH. B: Represen
by metformin for 15 min. The blot layout is in the same order as the graphand gonadotropin receptor concentration. In a previous
study, Espey suggested that the ovulatory process involves
inflammatory changes [29].
It has been recognized that cells usually control their
growth and proliferation through a complex of intracellular
signaling networks that integrate the environmental signals,
energy sources, and availability of nutrients. Consequently,
the balance of the signaling activities of the components of
intracellular networks is necessary for proper development.
AMPK is a heterotrimeric protein that responds to in-
creases in the ratio of adenosine-5′-monophosphate
(AMP)-ATP by inducing catabolic processes that pro-
duce ATP, and by repressing energy-consuming anabolicGN cells treated with TNF-α (1nM) and metformin (1 mM) (n = 4).
tative blots illustrating the effect of treatment on pIκB and GAPDH
in B.
Figure 5 The phosphorylation of p4E-BP1 and p70S6kinase. The phosphorylation of p4E-BP1 and p70S6kinase in KGN cells treated with
AICAR (1 mM) and metformin (1 mM) (n = 4). The phosphorylation of p4E-BP1 and p70S6kinase was quantified against GAPDH. A: Representative
blots illustrating the effect of treatment on pAMPK and GAPDH by AICAR (1 mM) for 4 h to 72 h (n = 4). The blot layout is in the same order as
the graph in panels B (p70S6K) and C (4E-BP1), respectively. D: Representative blots illustrating the effect of treatment on pAMPK and GAPDH by
metformin (1 mM) for 4 h to 72 h (n = 4). The blot layout is in the same order as the graph in panels E (p70S6K) and F (4E-BP1), respectively.
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has been reportedly used as a pharmacological activator
of AMPK in several reports [23,24].
The AMPK-mediated suppression of protein synthesis
including peptide hormones, growth factors, cytokines
and chemokines results in the inhibition of substances
contributing to cell growth.
In the present study, we demonstrated that AMPK, which
was activated by AICAR or metformin, suppressed the
TNF-α-induced IL-8 and GROα production via the inhib-
ition of an intracellular signal transduction system in KGN
cells. It was reported that AMPK suppressed the TNFα-
induced cytokine production in other cells [32]. They sug-
gest that AMPK activation attenuates the cytokine-induced
expression of proinflammatory and adhesion molecule genes
by inhibiting NF-κB activation [32]. Metformin, which be-
long to biguanide family, also inhibits the expression of pro-
inflammatory chemokines by blocking phosphorylation and
subsequent degradation of IκB-α (Figure 4). These data sug-
gest that AICAR or metformin might suppress TNF-α-
induced NFκB activation by IκB phosphorylation.
We also observed that the phosphorylation of IκB stimu-
lated by TNF-α was reduced by AICAR- or metformin-
induced AMPK activation. NFκB what dissociated from IκB
and subsequently shepherded to the nucleus, was also
thought to be suppressed by AICAR and by metformin. Onthe basis of present observations, IL-8 and GROα in FF are
thought to lead to neutrophil chemoattraction and accumu-
lation. As our results also indicated that IL-8 and GROα are
regulated by a mechanism involving TNF-α, it is likely that
IL-8 and GROα may play an important role in the accumu-
lation of neutrophils and in the subsequent induction of
ovulation [33]. It has been suggested that IL-8 and GROα
may be important modulators of preovulatory events, not
only by attracting and activating neutrophils that will even-
tually play a role in timely follicular rupture, but also by
stimulating new blood vessel formation for the corpus
luteum [19]. On the other hand, the elevation of not only
white blood count and neutrophil count but also TNF-α, IL-
6, CRP in serum levels have been implicated in pathphysio-
logical findings of PCOS compared with age- and /body
mass index- matched controls [34-36].
It has been reported that both mammalian targets of rapa-
mycin (mTOR) complex (i.e., mTORC1 and mTORC2)
modulate multiple cellular functions [37,38]. It was also rec-
ognized that mTORC1 regulates the activity of the
eukaryotic initiation factor 4E-BP1 and the serine/threonine
kinase ribosomal protein p70S6K, via interactions between
these proteins and Raptor. When 4E-BP1 is hypophosphory-
lated, it can block protein translation by binding to
eukaryotic translation initiation factor 4 epsilon (eIF4E)
through eIF4 gamma (eIF4G), a protein that leads mRNA to
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leads to the dissociation of 4E-BP1 from eIF4E, allowing
eIF4G to the beginning of mRNA translation [40]. In the
present study, we found that the phosphorylations of 4EBP-
1 and p70S6K which coexists with the downstream, were
also attenuated by AMPK activation. These findings provide
evidence that AMPK may contribute to both of transcrip-
tion and translation in human granulosa cells.
Our study may delineate that elevation of proinflam-
matory cytokines such as TNF-α in women with PCOS
contribute to the overproduction of IL-8 and GROα
leading to the exacerbation of intraovarian circum-
stance. Metformin, which is administered to PCOS pa-
tients with insulin resistance, can influence not only the
systemic regulation of hyperinsulinemia but also the
modulation of intracellular molecules in the granulosa
cells. Moreover, Gleicher et al. reported that the cause
of PCOS has similarity to autoimmune disease, because
active antibodies to steroidogenic enzymes in adrenal
and ovary have been investigated [41]. Metformin may
contribute to suppress these inflammatory reaction. A
limitation of our study is that we used not primary cul-
tured granulosa cells but a tumor cell line, because more
number of cells with fixed condition for protein analysis
is needed in this study.
This is a first report that metformin could affect TNF-α-
induced IL-8 and GROα production and the molecular
levels of signal transduction pathways in granulosa cells,
which may contribute to improve intraovarian circumstance
in women with PCOS patients. It was reported that the
beneficial effects of metformin as a reduction of inflamma-
tory reaction was admitted in Diabetes Mellitus. These ef-
fects are direct and independent on glucose levels [42].
Further investigations are necessary to elucidate the
mechanisms of metformin’s actions. Taken together, our
results demonstrate a new role for the molecular mechan-
ism of metformin in the improvement of reproductive
function in PCOS.Abbreviations
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